Table 1.
Characteristics of the RCTs and patients included in the meta-analysis
| Number | Author/year | NCT Number | Nation | Study phase | Interventions | Sample size | Median age (P/C) years | Median treatment duration (P/C) | Cancer type | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PARP group | Control group | PARP inhibitor group | Control group | ||||||||
| 1 |
Kaye [18] et.al 2011 |
NCT00628251 | United States, Australia, etc | II | Olaparib (400 mg/day) | Liposomal doxorubicin | 32 | 32 | 58.5/53 | NA | Ovarian cancer |
| Olaparib (800 mg/day) | 32 | 53.5/53 | NA | Ovarian cancer | |||||||
| 2 |
Ledermann [19] et.al 2012 |
NCT00753545 | United States, Austria, etc | II | Olaparib (800 mg/day) | Placebo | 136 | 128 | 58/59 | 206.5/141 days | Ovarian cancer |
| 3 |
Pusztai [20] et.al 2021 |
NCT01042379 | United States | II |
Olaparib (200 mg/day) + Durvalumab + Paclitaxel + Doxorubicin + Cyclophosphamide |
Paclitaxel + Doxorubicin + Cyclophosphamide | 73 | 299 | 46/48 | NA | Breast cancer |
| 4 |
Rugo [21] et.al 2016 |
II |
Veliparib (100 mg/day) + Carboplatin + Paclitaxel |
Carboplatin + Paclitaxel | 72 | 44 | 48.5/47.5 | 182/165 days | Breast Cancer | ||
| 5 |
Novello [22] et.al 2014 |
NCT01086254 | France, Germany, etc | II | Iniparib (11.2 mg/kg/week) + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin | 78 | 39 | 59/58 | 15/13.9 weeks | Lung cancer |
| 6 |
Han [23] et.al 2018 |
NCT01506609 | United States, Australia, etc | II |
Veliparib (240 mg/day) + Carboplatin + Paclitaxel |
Placebo + Carboplatin + Paclitaxel |
93 | 96 | 44/46 | 36/30 weeks | Breast Cancer |
|
Veliparib (80 mg/day) + Temozolomide |
93 | 46/46 | 18/30 weeks | Breast Cancer | |||||||
| 7 |
Hussain [24] et.al 2017 |
NCT01576172 | United States | II | Veliparib (600 mg/day) + Abiraterone acetate + Prednisone | Abiraterone acetate + Prednisone | 79 | 74 | 68/69 | 36/36 weeks | Prostate Cancer |
| 8 |
Owonikoko [25] et.al 2020 |
NCT01642251 | United States | II |
Veliparib (200 mg/day) + Etoposide + Cisplatin |
Placebo + Etoposide + Cisplatin |
66 | 66 | 66/64 | NA | Lung Cancer |
| 9 |
Fennell [26] et.al 2022 |
NCT01788332 | United Kingdom | II | Olaparib (600 mg/day) | Placebo | 31 | 38 | 65/63 | 12/12 weeks | Lung cancer |
| 10 |
Banerjee [27] et.al 2021 |
NCT01844986 | United States, Canada, etc | III | Olaparib (600 mg/day) | Placebo | 260 | 130 | NA | 24.6/13.9 months | Ovarian cancer |
| 11 |
Mirza [28] et.al 2016 |
NCT01847274 | United States, Italy, etc | III | Niraparib (300 mg/day) | Placebo | 367 | 179 | NA | NA | Ovarian cancer |
| 12 |
Bang [29] et.al 2017 |
NCT01924533 | China, Japan, etc | III | Olaparib (200 mg/day) + Paclitaxel | Placebo + Paclitaxel | 262 | 259 | 58/59 | 73.5/59 days | Gastric cancer |
| 13 |
Ledermann [30] et.al 2021 |
NCT01968213 | United States, Australia, etc | III | Rucaparib (1200 mg/day) | Placebo | 372 | 189 | 61/62 | 8.3/5.5 months | Ovarian cancer |
| 14 |
Clarke [31] et.al 2018 |
NCT01972217 | United States, Canada, etc | II | Olaparib (600 mg/day) + Abiraterone | Pacebo + Abiraterone | 71 | 71 | 70/67 | 309/253 days | Prostate cancer |
| 15 |
Loibl [32] et.al 2018 |
NCT02032277 | United States, Australia, etc | III | Veliparib (100 mg/day) + Paclitaxe + Carboplatin |
Veliparib placebo + Paclitaxel + Carboplatin |
313 | 158 | 51/49 | 89/85.5 days | Breast cancer |
|
Veliparib placebo + Paclitaxel + Carboplatin placebo |
157 | 51/50 | 89/84 days | Breast cancer | |||||||
| 16 |
Diéras [33] et.al.2020 |
NCT02163694 | United States, Australia, etc | III | Veliparib (240 mg/day) + Carboplatin + Paclitaxel | Placebo + Carboplatin + Paclitaxel | 336 | 171 | 47/45 | NA | Breast cancer |
| 17 |
Golan [34] et.al 2020 |
NCT02184195 | United States, Canada, etc | III | Olaparib (600 mg/day) | Placebo | 90 | 61 | 57/57 | 6/3.7 months | Pancreatic Cancer |
| 18 |
Gorbunova [35] et.al 2019 |
NCT02305758 | North America, Australia etc | II |
Veliparib (400 mg/day) + Irinotecan + Leucovorin + Fluorouracil infusion ± Bevacizumab |
Irinotecan + Leucovorin + Fluorouracil bolus + Fluorouracil infusion ± Bevacizumab | 65 | 65 | 59/64 | NA | Colorectal Cancer |
| 19 |
Liu [36] et.al 2022 |
NCT02446600 | United States, Canada, Japan | III | Olaparib (600 mg/day) | Platinum-based chemotherapy | 187 | 167 | NA | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Olaparib (400 mg/day) + Cediranib | 183 | NA | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | |||||||
| 20 |
Coleman [37] et.al 2019 |
NCT02470585 | United States, Australia, etc | III | Veliparib (300 mg/day) + Carboplatin + Paclitaxel + followed by veliparib (600 mg or 800 mg/day) maintenance |
Placebo + Carboplatin + Paclitaxel + followed by Placebo maintenance |
377 | 371 | 62/62 | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Veliparib (300 mg/day) + Carboplatin + Paclitaxel + followed by Placebo maintenance | 376 | 62/62 | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | |||||||
| 21 |
Ray-Coquard [38] et.al 2019 |
NCT02477644 | Austria, Belgium, etc | III |
Olaparib (600 mg/day) + Bevacizumab |
Placebo + Bevacizumab | 535 | 267 | 61/60 | 17.3/15.6 moths | Ovarian cancer |
| 22 |
González-Martín [39] et.al 2019 |
NCT02655016 | United States, France, etc | III | Niraparib (200 mg or 300 mg/day) | Placebo | 484 | 244 | 62/62 | NA | Ovarian cancer |
| 23 |
Kristeleit [40] et.al 2022 |
NCT02855944 | United States, Brazil, etc | III | Rucaparib (1200 mg/day) | Chemotherapy (administered per institutional guidelines) | 232 | 113 | 58/59 | 7.3/3.6 months | Ovarian cancer |
| 24 |
Chiorean [41] et.al 2021 |
NCT02890355 | United States | II |
Veliparib (400 mg/day) + Irinotecan + Folinic acid + 5-Fluorouracil infusion |
Irinotecan + Folinic acid + 5-Fluorouracil bolus + 5-Fluorouracil infusion |
56 | 50 | 67/67 | 8/10 weeks | Pancreatic Cancer |
| 25 |
Bono [42] et.al 2020 |
NCT02987543 | United States, Canada, etc | III | Olaparib (600 mg/day) | Physician’s choice of enzalutamide or abiraterone | 256 | 130 | NA | 7.4/3.9 months | Prostate Cancer |
| 26 |
Colombo [43] et.al 2022 |
NCT03314740 | Italy | II | Olaparib (600 mg/day) every day + Cediranib every day | Paclitaxel | 41 | 28 | 64.2/62.5 | NA | Ovarian cancer |
| Olaparib (600 mg/day) every day + Cediranib 5 days a week | 41 | 59.9/62.5 | NA | Ovarian cancer | |||||||
| 27 |
Ai [44] et.al 2021 |
NCT03516084 | China | III | Niraparib (300 or 200 mg/day) | Placebo | 125 | 60 | NA | 44/42.5 days | Lung Cancer |
| 28 |
Monk [45] et.al 2022 |
NCT03522246 | United States, Australia, etc | III | Rucaparib (1200 mg/day) | Placebo | 425 | 110 | 61/61 | 14.7/9.9 month | Ovarian cancer |
| 29 |
Wu [46] et.al 2020 |
NCT03705156 | China | III | Niraparib (300 mg or 200 mg/day) | Placebo | 177 | 88 | 53/55 | 369/171 days | Ovarian cancer |
| 30 |
Woll [47] et.al 2022 |
/ | United Kingdom | II | Olaparib (300 mg twice a day) | Placebo | 73 | 74 | 66/64 | 8/8 weeks | Lung cancer |
| Olaparib ( 200 mg three times a day) | Placebo | 73 | 63/64 | 19/8 weeks | Lung cancer | ||||||
| 31 |
Sun [48] et.al 2022 |
/ | China | II | Olaparib (400 mg/day) + Bevacizumab | Albumin-bound paclitaxel + Bevacizumab | 42 | 42 | NA | NA | Ovarian cancer |
| 32 |
O’Reilly [49] et.al 2020 |
/ | United States, Canada, Israel | II |
Veliparib (160 mg/day) + Cisplatin + Gemcitabine |
Cisplatin + Gemcitabine | 27 | 23 | 64/63 | NA | Pancreas Adenocarcinoma |
NCT number national clinical trial number, PARP poly(adenosine diphosphate-ribose) polymerase, NA not reported / Not registered on the ClinicalTrials.gov, P/C PARP inhibitor group/control group